Using transcriptome data from more than 38,600 tumor samples, investigators flagged expression patterns that may coincide with higher SARS-CoV-2 infections.
Within the KiCS study researchers found targetable mutations in more than half of the kids, but few actually received drugs based on those molecular markers.
Interim results from a study in the Netherlands suggest whole-genome sequencing can be done fast enough to uncover treatment targets in metastatic cancer patients.
Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.
Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.
Adult participants will have access to saliva-based testing from Invitae for the Screen Project, which aims to find clinically actionable BRCA1/2 mutations.
A Sanford Cancer Center team is genomically profiling head and neck squamous cell cancer samples to look for biomarkers of immunotherapy and chemoradiation response.
With at-home testing and online, patient-centered reports, the CureCloud initiative sets out to break down barriers to targeted treatment options while building a broad patient dataset.
Investigators plan to tap into large genomic and other datasets with an in silico patient to simulate drug responses, uncover treatment targets, and assess therapies.
With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.